Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | HER2CLIMB: tucatinib with trastuzumab and capecitabine for HER2+ breast cancer with brain metastases

Heather McArthur • 3 Jun 2020
ASCO 2020
Breast Cancer Antibodies Capecitabine Trastuzumab Tucatinib
HER2CLIMB

Heather McArthur, MD, MPH, of Cedars-Sinai Medical Center, Los Angeles, CA, outlines the exploratory efficacy analyses in patients with brain metastases enrolled in the HER2CLIMB trial (NCT02614794), which evaluated tucatinib versus placebo in combination with capecitabine and trastuzumab in patients with advanced HER2+ breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Heather McArthur

2:05
TROPION-Breast04: Dato-DXd and durvalumab in TNBC or HR-low/HER2- breast cancer
Heather McArthur • 13 Dec 2023
1:56
Management of ER+ breast cancer with checkpoint inhibitors
Heather McArthur • 13 Dec 2023
1:37
How can we best sequence ADCs in breast cancer?
Heather McArthur • 13 Dec 2023
1:51
Managing ADC-related toxicity in breast cancer
Heather McArthur • 13 Dec 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals